JP2019526612A - 認知症を治療するための組成物 - Google Patents

認知症を治療するための組成物 Download PDF

Info

Publication number
JP2019526612A
JP2019526612A JP2019513926A JP2019513926A JP2019526612A JP 2019526612 A JP2019526612 A JP 2019526612A JP 2019513926 A JP2019513926 A JP 2019513926A JP 2019513926 A JP2019513926 A JP 2019513926A JP 2019526612 A JP2019526612 A JP 2019526612A
Authority
JP
Japan
Prior art keywords
estradiol
acid
dementia
composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526612A5 (enExample
Inventor
スティーブン・ホフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019526612A publication Critical patent/JP2019526612A/ja
Publication of JP2019526612A5 publication Critical patent/JP2019526612A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513926A 2016-09-12 2017-09-08 認知症を治療するための組成物 Pending JP2019526612A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662393140P 2016-09-12 2016-09-12
US62/393,140 2016-09-12
US201762507531P 2017-05-17 2017-05-17
US62/507,531 2017-05-17
PCT/US2017/050653 WO2018049141A1 (en) 2016-09-12 2017-09-08 Compositions for treating dementia

Publications (2)

Publication Number Publication Date
JP2019526612A true JP2019526612A (ja) 2019-09-19
JP2019526612A5 JP2019526612A5 (enExample) 2020-10-08

Family

ID=59901615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513926A Pending JP2019526612A (ja) 2016-09-12 2017-09-08 認知症を治療するための組成物

Country Status (12)

Country Link
US (1) US10300077B2 (enExample)
EP (1) EP3509639A1 (enExample)
JP (1) JP2019526612A (enExample)
KR (1) KR20190072521A (enExample)
CN (2) CN114796236A (enExample)
AU (1) AU2017322332A1 (enExample)
BR (1) BR112019004540A2 (enExample)
CA (1) CA3036511A1 (enExample)
IL (1) IL265255A (enExample)
MX (1) MX2019002673A (enExample)
PH (1) PH12019500479A1 (enExample)
WO (1) WO2018049141A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) * 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
JP2003245054A (ja) * 2001-07-31 2003-09-02 Daicho Kikaku:Kk 健康食品
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
JP2008534505A (ja) * 2005-03-25 2008-08-28 メルク エンド カムパニー インコーポレーテッド テストステロンサプリメントおよび５アルファ−レダクターゼインヒビターによる男性の治療方法
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
JP2009545605A (ja) * 2006-08-02 2009-12-24 ユニバーシティ オブ サザン カリフォルニア フィトエストロゲン製剤およびその使用
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03161442A (ja) * 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US7338971B2 (en) * 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
CA2617934A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation
WO2010118282A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06100466A (ja) * 1992-02-14 1994-04-12 Tsumura & Co ストレス性脳神経細胞器質障害防御剤
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
JP2003245054A (ja) * 2001-07-31 2003-09-02 Daicho Kikaku:Kk 健康食品
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
JP2008534505A (ja) * 2005-03-25 2008-08-28 メルク エンド カムパニー インコーポレーテッド テストステロンサプリメントおよび５アルファ−レダクターゼインヒビターによる男性の治療方法
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
JP2009545605A (ja) * 2006-08-02 2009-12-24 ユニバーシティ オブ サザン カリフォルニア フィトエストロゲン製剤およびその使用
JP2016520615A (ja) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF NEUROLOGY, vol. 57, JPN6021019213, 2000, pages 1586 - 1591, ISSN: 0004912228 *
BMC MEDICINE, vol. 11, no. 74, JPN6021019212, 2013, pages 1 - 17, ISSN: 0004912227 *
NEUROLOGY, vol. 70, no. 1, JPN6021019211, 2008, pages 17 - 24, ISSN: 0004912226 *

Also Published As

Publication number Publication date
PH12019500479A1 (en) 2019-07-29
US20180071316A1 (en) 2018-03-15
AU2017322332A1 (en) 2019-04-04
CA3036511A1 (en) 2018-03-15
WO2018049141A1 (en) 2018-03-15
EP3509639A1 (en) 2019-07-17
CN114796236A (zh) 2022-07-29
US10300077B2 (en) 2019-05-28
CN110177572A (zh) 2019-08-27
KR20190072521A (ko) 2019-06-25
IL265255A (en) 2019-05-30
BR112019004540A2 (pt) 2019-05-28
WO2018049141A4 (en) 2018-05-03
MX2019002673A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
US11357793B2 (en) Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
Traish et al. Dehydroepiandrosterone (DHEA)—a precursor steroid or an active hormone in human physiology (CME)
JP5289281B2 (ja) Ｃｎｓ疾患の治療において使用するためのプレグナンステロイド
TWI258369B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors
US12415829B2 (en) Progesterone phosphate analogs and uses related thereto
JP2009511609A5 (enExample)
US10300077B2 (en) Compositions and methods for treating dementia
WO2007144152A2 (en) Extended step-down estrogen regimen
JP2016527307A5 (enExample)
US11274118B2 (en) Progesterone analogs and uses related thereto
EP2371367A1 (en) Method of treating men with testosterone supplement and 5alpha reductase inhibitor
EP3116510A1 (en) Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
Fedotcheva et al. Dehydroepiandrosterone and Its Metabolite 5-Androstenediol: New Therapeutic Targets and Possibilities for Clinical Application
JP2019526612A5 (enExample)
EP1123100B1 (en) Improving memory by the administration of delta 5-androstene-3 beta-ol-7,17-dione and 3 beta esters thereof
JP2014508809A (ja) アンドロゲンを用いたミエリン再生
TW200730180A (en) Therapeutic uses of steroidal compounds
EP4429669A1 (en) Steroid as a modulator of gabaa receptor
TW201402126A (zh) 用於治療子宮內膜異位症之固醇硫酸酯酶抑制劑之組合
Anita et al. Use of Progestogens in Clinical Practice of Obstetrics and Gynecology
JP2005518412A5 (enExample)
US20110092470A1 (en) Method of treating men with erectile dysfunction
GENAZZANI et al. methods, techniques, drugs
Aristizábal Linares et al. Effectiveness of Naltrexone in the Treatment of Severe Pruritus
TW200306197A (en) Medicament for treating climacteric post-menopausal complaints

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200824

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221102